Michael Weiner Email and Phone Number
Michael Weiner work email
- Valid
- Valid
- Valid
- Valid
- Valid
Michael Weiner personal email
Michael Weiner phone numbers
Serial Scientific Entrepreneur. Founder and CEO of Abbratech and Precision Biotools. Inventor of site-directed antibodies.Notable life sciences tools developed (all published in scientific peer reviewed literature and most issued US patents) include: 1st to clone and sequence BamHI (Ph.D. thesis, Cornell Univ.), 1st to code the use of a rolling hash computer algorithm for DNA analysis, sole inventor of QuikChange Mutagenesis, pCR-Script directional blunt-ended cloning method, paired-end DNA sequencing, emulsion PCR (454 Life Sciences), droplet PCR (RainDance Technologies), HT Y2H for protein::protein interaction, (GlaxoSmithKline), HT phage display for Ab discovery (Affomix), inventor of DNA bar-coded Luminex beads for multiplex DNA genotyping, expanded radix algorithm for more efficient DNA sequence storage (Illumina), invented the pMINERVA scFv to IgG cloning and expression system (AxioMx). Inventor in NextGen DNA sequencing, and NextGen Proteomics sequencingFounder of Affomix (proteomics, acquired by Illumina), AxioMx (proteomics, acquired by Abcam), GnuBio (NextGen DNA sequencing, acquired by BioRad), and Encodia (NextGen protein sequencing). Director of The Rothberg Institute for Childhood Diseases and CSO of 454 Life Sciences (NextGen DNA Sequencing, Acquired by Roche) and RainDance Technologies (microfluidics, acquired by BioRad).Co-author of papers and named inventor on numerous patents. Editor for BioTechniques and serves on several SABs and BoDs. Member of several NIH review panels and has been awarded over $30M in R01, R21, SBIR Phase I and II, Fast-track, Direct-to Phase II, U19 and U53 grant. Awarded DARPA funding. Winner of both Connecticut Entrepreneur of the year and CiteAb lifetime achievement awards.Ph.D. in Genetics from Cornell University cloning, sequencing and characterizing the psm genes of temperate bacteriophages of Bacillus species, including M.BamHI. Minors in Microbiol. and Biochem. Post-doc designing, synthesizing Thrombin, RNaseA genes, investigated protein refolding under Dr H. Scheraga (Dept of Physical Chemistry, Cornell University).Professional ceramicist, specializing in macro-crystalline glazes and image-transfer onto clay. Invented and submitted several novel methods for image transfer onto clay in Pottery Making Illustrated and has taught several ceramics workshops at Guilford Art Center and Wesleyan Pottery Studio.Scientific specialties: Tech dev: Genetics, Genomics, Mol. Biol., Proteomics, biol. applications in emulsions and small volumes (<50 pL), DNA sequencing, Bioeng., Instrumentation
-
Founder And CeoAbbratech And Precision Biotools Dec 2020 - PresentPrecision-targeted therapeutic antibodies based on our proprietary 'Epivolve' technology.
-
Co-FounderEncodia Jan 2017 - PresentSan Diego, Ca, UsWe are a privately held biotech company developing a highly-parallelized protein analysis platform. "Our vision is to transform biomedical research by delivering next-gen proteomics technology."
-
OwnerNext Generation Tile (Nextgen Tile) May 2010 - PresentPrivate outlet for sale of ceramics and other artwork.
-
V.P. ResearchAbcam Nov 2015 - Jan 2021Cambridge, Cambridgeshire, GbAxioMx was acquired by Abcam on November 11, 2015. Being able to access the tools already in place at Abcam and leveraging the technology we developed at AxioMx will be an incredible opportunity. My immediate goal is to make this integration succeed with zero down-time. -
Founder And Chief Scientific OfficerAxiomx Inc. (Acquired By Abcam In 2015) Feb 2012 - Nov 2015It currently takes 4-6 months to generate high-affinity, high specificity reagents. Through advances in automation, molecular biology and genetics, my AxioMx goal is to reduce this time period to less than 2 weeks.
-
Founder And Scientific ConsultantGnubio, Inc (Acquired By Biorad In 2014) Jan 2008 - Jan 2014Cambridge, Ma, UsCompany founder and Scientific Consultant. GnuBio uses microfluidics and proprietary emulsion libraries to sequence DNA. -
Founder And CsoAffomix Corp (Acquired By Illumina, Inc In 2010) 2006 - Jan 2012Company founder and CSO. Affomix developed automated methods to screen for antibodies against peptide and protein antigens. We invented the use of microemulsions for screening phage display libraries by fluorescence-activated cell sorting (FACS). Prior to the Illumina acquisition we brought in over $4MM in NIH grant and external contract funding and raised over $7M in VC funding.
-
V.P., Molecular SciencesRaindance Technologies 2003 - 2007Billerica, Ma, UsAs one of the first employees at RainDance Technologies, M.Weiner invented and helped develop a droplet tracking scheme for emulsion library constituents and co-invented the use of emulsion PCR for target-sequence amplification for Next-generation DNA sequencers. Additional applications he developed included single-enzyme and single-cell analysis in micro-droplets. -
DirectorRothberg Institute 2002 - 2006Developed phage-display and emulsion-based screening methodology for antibody-therapeutic treatments for tuberous sclerosis complex (TSC). Led team that developed first cell-based model system for TSC. Led team that analyzed TSC tissues for up-regulated genes involved in TSC tumors.
-
V.P., Molecular Sciences454 Life Sciences 2000 - 2003Branford, Ct, UsDr Weiner co-invented the first commercial Next-generation DNA sequencer and was a co-inventor of emulsion PCR for template preparation for Next-generation DNA sequencing. He led research and development for both the Molecular Biology and Engineering teams for the first 3 years of 454's existence and brought in over $10MM in NIH funding. -
Head, Dept. Of Genomic SciencesGlaxosmithkline 1995 - 2000Brentford, Middlesex, GbInvented and developed: 1) Luminex-based SNP genotyping using DNA ZipCoded beads, 2) automated high-throughput yeast two-hybrid system, 3) new multifunctional expression vectors for baculoviral and adenoviral expression in insect and mammalian cells. Head of department responsible for DNA sequencing and gene expression analysis for the RTP site and a member of the Nuclear Receptor group. -
Sr. Staff ScientistStratagene 1989 - 1995UsAt Stratagene Dr Weiner invented and developed several products for the reagent marketplace, including: Quikchange, (a method for site-directed mutagenesis) and pCRScript, a system for cloning PCR fragments.
Michael Weiner Skills
Michael Weiner Education Details
-
Cornell UniversityPhysical Chemistry -
Cornell UniversityGenetics
-
Penn State UniversityMicrobiology And Immunology
-
Council Rock High SchoolAcademic
Frequently Asked Questions about Michael Weiner
What company does Michael Weiner work for?
Michael Weiner works for Encodia
What is Michael Weiner's role at the current company?
Michael Weiner's current role is Founder of Abbratech, Precision Biotools and Encodia.
What is Michael Weiner's email address?
Michael Weiner's email address is mw****@****dia.com
What is Michael Weiner's direct phone number?
Michael Weiner's direct phone number is +120360*****
What schools did Michael Weiner attend?
Michael Weiner attended Cornell University, Cornell University, Penn State University, Council Rock High School.
What skills is Michael Weiner known for?
Michael Weiner has skills like Genomics, Molecular Biology, Biochemistry, Dna, Dna Sequencing, Biotechnology, Genetics, Proteomics, Lifesciences, High Throughput Screening, Genotyping, Sequencing.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial